Consumer medicine information

MS Mono Capsules

Morphine sulfate pentahydrate

BRAND INFORMATION

Brand name

MS Mono

Active ingredient

Morphine sulfate pentahydrate

Schedule

S8

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using MS Mono Capsules.

MS MONO® modified release capsules

MS MONO® modified release capsules


 Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.


WARNING: Important safety information is provided in a boxed warning in the full CMI. Read before using this medicine.

 1. Why am I using MS MONO capsules?

MS MONO capsules contain the active ingredient morphine sulfate pentahydrate. MS MONO capsules are used for the management of pain severe enough to require daily, long-term opioid treatment and for which other forms of treatment have failed or are otherwise inappropriate to provide sufficient management of pain.

For more information, see Section 1. Why am I using MS MONO capsules? in the full CMI.

 2. What should I know before I use MS MONO capsules?

Do not use if you have ever had an allergic reaction to morphine or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I use MS MONO capsules? in the full CMI.

 3. What if I am taking other medicines?

Some medicines may interfere with MS MONO capsules and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

 4. How do I use MS MONO capsules?
  • Your doctor will tell you exactly how much to take.
  • Follow the instructions given to you by your doctor or your pharmacist.
  • You must only take MS MONO capsules by mouth.

More instructions can be found in Section 4. How do I use MS MONO capsules? in the full CMI.

 5. What should I know while using MS MONO capsules?

Things you should do
  • Remind any doctor or dentist you visit that you are using MS MONO capsules.
  • Tell your doctor or pharmacist if you are taking any other medicines that you use to help you relax, anything that contains alcohol (like cough syrup) or other medicines that treat pain.
Things you should not do
  • Do not stop using this medicine suddenly.
  • Do not take more than your doctor tells you to.
Driving or using machines
  • MS MONO capsules may cause drowsiness. If affected, do not drive a vehicle or operate machinery.
Drinking alcohol
  • Avoid alcohol. Alcohol may make you feel more sleepy and could increase the risk of serious side effects, such as shallow breathing with the risk of stopping breathing and loss of consciousness.
Looking after your medicine
  • Store below 25°C.
  • Keep it where young children cannot reach it.

For more information, see Section 5. What should I know while using MS MONO capsules? in the full CMI.

 6. Are there any side effects?

MS MONO capsules may cause constipation, nausea, vomiting, dizziness, drowsiness and be habit forming if taken frequently or over long periods.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.


WARNING:

Limitations of use

MS MONO capsules should only be used when your doctor decides that other treatment options are not able to effectively manage your pain or you cannot tolerate them.

Hazardous and harmful use

MS MONO capsules poses risks of abuse, misuse and addiction which can lead to overdose and death. Your doctor will monitor you regularly during treatment.

Life threatening respiratory depression

MS MONO capsules can cause life-threatening or fatal breathing problems (slow, shallow, unusual or no breathing) even when used as recommended. These problems can occur at any time during use, but the risk is higher when first starting MS MONO capsules and after a dose increase, if you are older, or have an existing problem with your lungs. Your doctor will monitor you and change the dose as appropriate.

Use of other medicines while using MS MONO capsules

Using MS MONO capsules with other medicines that can make you feel drowsy such as sleeping tablets (e.g. benzodiazepines), other pain relievers, antihistamines, antidepressants, antipsychotics, gabapentinoids (e.g. gabapentin and pregabalin), cannabis and alcohol may result in severe drowsiness, decreased awareness, breathing problems, coma and death. Your doctor will minimise the dose and duration of use; and monitor you for signs and symptoms of breathing difficulties and sedation. You must not drink alcohol while using MS MONO capsules.

MS MONO® modified release capsules

Active ingredient: morphine sulfate pentahydrate


 Consumer Medicine Information (CMI)

This leaflet provides important information about using MS MONO capsules. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using MS MONO capsules.

Where to find information in this leaflet:

1. Why am I using MS MONO capsules?
2. What should I know before I use MS MONO capsules?
3. What if I am taking other medicines?
4. How do I use MS MONO capsules?
5. What should I know while using MS MONO capsules?
6. Are there any side effects?
7. Product details

1. Why am I using MS MONO capsules?

MS MONO capsules contain the active ingredient morphine sulfate pentahydrate. Morphine belongs to a group of medicines called opioid analgesics.

MS MONO capsules are indicated for the management of severe pain where:

  • other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and
  • the pain is opioid-responsive, and
  • requires daily, continuous, long-term treatment.
2. What should I know before I use MS MONO capsules?

Warnings

Do not use MS MONO capsules if:

  • you are allergic to morphine, or any of the ingredients listed at the end of this leaflet. Always check the ingredients to make sure you can use this medicine.
  • you have acute breathing difficulties such as bronchitis or asthma
  • you have severe abdominal pain with bloating, cramps or vomiting
  • you have a condition where your small bowel does not work properly
  • you take medicine for depression called a 'monoamine oxidase inhibitor' or have taken any in the last two weeks
  • you are pregnant or in labour.

Check with your doctor if you:

  • are severely drowsy, have a reduced level of consciousness or are feeling faint or dizzy upon standing
  • have heart problems or heart disease
  • have low blood pressure
  • have chronic lung disease
  • suffer from sleep apnoea (temporarily stop breathing while you sleep)
  • have just drunk a large amount of alcohol, regularly drink large amounts of alcohol or have confusion and shaking due to stopping drinking alcohol
  • suffer from convulsions, fits or seizures
  • have a head injury, brain tumour or increased pressure in your head
  • are about to have surgery, had recent gastrointestinal surgery or have had other surgery in the last 24 hours
  • have chronic liver or kidney disease
  • have increased prostate size or difficulty passing urine
  • have problems with your gall bladder
  • have problems with or recent surgery of your bile duct
  • have inflammation of the pancreas
  • have adrenal glands which are not working properly
  • have an underactive thyroid gland
  • have a severe mental condition involving losing contact with reality or an inability to think clearly
  • have an addiction or history of abuse of alcohol, opioids or other drugs.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

MS MONO capsules given to the mother during labour can cause breathing problems and signs of withdrawal in the newborn.

Talk to your doctor if you are breastfeeding or intend to breastfeed. Low levels of opioid analgesics have been detected in human milk.

Addiction

You can become addicted to MS MONO capsules even if you take it exactly as prescribed. MS MONO capsules may become habit forming causing mental and physical dependence. If abused, it may become less able to reduce pain.

Dependence

As with all other opioid containing products, your body may become used to you taking MS MONO capsules. Taking it may result in physical dependence. Physical dependence means that you may experience withdrawal symptoms if you stop taking MS MONO capsules suddenly, so it is important to take it exactly as directed by your doctor.

Tolerance

Tolerance to MS MONO capsules may develop, which means that the effect of the medicine may decrease. If this happens, more may be needed to maintain the same effect.

Withdrawal

Continue taking your medicine for as long as your doctor tells you. If you stop having this medicine suddenly, your pain may worsen and you may experience some or all of the following withdrawal symptoms:

  • nervousness, restlessness, agitation, trouble sleeping or anxiety
  • body aches, weakness or stomach cramps
  • loss of appetite, nausea, vomiting or diarrhoea
  • increased heart rate, breathing rate or pupil size
  • watery eyes, runny nose, chills or yawning
  • increased sweating.
3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with MS MONO capsules and affect how it works.

Using MS MONO capsules with medicines that can make you feel drowsy may result in severe drowsiness, decreased awareness, breathing problems, coma and death. These medicines include:

  • sleeping tablets and other sedatives (including benzodiazepines and barbiturates)
  • gabapentinoids
  • cannabis
  • antihistamines
  • anxiolytics
  • general anaesthetics
  • antiemetics
  • antidepressants (including tricyclic antidepressants)
  • antipsychotics (including phenothiazines)
  • neuroleptics
  • beta-blockers (medicines used to treat high blood pressure)
  • other opioids
  • alcohol.

MS MONO capsules may enhance the action of neuromuscular blocking agents (medicines used to relax muscles) and affect your breathing.

MS MONO capsules may increase the anticoagulant activity of coumarin and other anticoagulants (medicines used to prevent blood clots).

MS MONO capsules should not be used if you are taking non-selective monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such treatment.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect MS MONO capsules.

4. How do I use MS MONO capsules?

How much to take

  • Your doctor will tell you how much to take.
  • Follow the instructions provided and use MS MONO capsules until your doctor tells you to stop.

When to take MS MONO capsules

  • Take MS MONO capsules every 24 hours or as directed by your doctor.
  • Take MS MONO capsules at about the same time each day.
  • You can take MS MONO cpasules before or after a meal.

How to take MS MONO capsules

Swallow MS MONO capsules whole with water.

If you have trouble swallowing, you can open your capsules and sprinkle the pellets onto soft cold food such as yoghurt, custard, apple puree or ice cream. Eat the soft food containing the pellets within 60 minutes. Do not chew or crush the pellets. After eating, rinse your mouth to ensure that all the pellets have been swallowed.

The pellets may also be sprinkled into a glass of liquid (milk, orange juice or water). Drink the liquid containing the pellets within 60 minutes. Do not chew or crush the pellets. If some pellets stick to the glass, add more liquid and swirl to pick up any remaining pellets before drinking.

Do not chew or crush them.

The pellets may release all their contents at once if the pellets are chewed or crushed, which can be dangerous and cause serious problems, such as an overdose which may be fatal.

If you forget to use MS MONO capsules

You should take MS MONO capsules at the same time each day. If you miss your dose at the usual time, you may take MS MONO capsules as soon as you remember.

If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.

Do not take a double dose to make up for the dose you missed.

This may increase the chance of getting unwanted side effects including severe drowsiness, decreased awareness, breathing problems, coma and death.

If you use too much MS MONO capsules (overdose)

If you or someone else receive too much (overdose), and experience one or more of the symptoms below, call triple zero (000) for an ambulance. Keep the person awake by talking to them or gently shaking them every now and then. You should follow the above steps even if someone other than you have accidentally used MS MONO capsules that was prescribed for you. If someone takes an overdose, they may experience one or more of the following symptoms:

  • slow, unusual or difficult breathing
  • drowsiness, dizziness or unconsciousness
  • slow or weak heartbeat
  • nausea or vomiting
  • convulsions or fits.

If you think you or someone else may have used too much MS MONO capsules you should immediately:

  • phone the Poisons Information Centre (by calling 13 11 26), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

When seeking medical attention, take this leaflet and remaining medicine with you to show the doctor. Also tell them about any other medicines or alcohol which have been taken.

5. What should I know while using MS MONO capsules?

Things you should do

Call your doctor straight away if you:

  • become pregnant
  • feel your pain is getting worse.

Remind any doctor or dentist or pharmacist you visit that you are using MS MONO capsules.

If you are going to have surgery, tell the surgeon or anaesthetist that you are taking this medicine.

Things you should not do

Do not stop using this medicine suddenly. If you stop taking MS MONO capsules suddenly, your pain may worsen and you may experience withdrawal symptoms.

Do not take MS MONO capsules to treat any other complaint unless your doctor tells you to.

Do not give this medicine to anyone else, even if they have the same condition as you.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how MS MONO capsules affect you.

MS MONO capsules may cause drowsiness or impair mental and/or physical ability in some people.

Drinking alcohol

Tell your doctor if you drink alcohol.

Alcohol may make you feel more sleepy, and could increase the risk of serious side effects, such as shallow breathing with the risk of stopping breathing and loss of consciousness.

Looking after your medicine

  • Store below 25°C.

Follow the instructions on the carton on how to take care of your medicine properly.

Store it in a cool dry place away from moisture, heat or sunlight; for example, do not store it:

  • in the bathroom or near a sink, or
  • in the car or on window sills.

Keep it where young children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Getting rid of any unwanted medicine

If the medicine is damaged, you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effectsWhat to do
Gastrointestinal and urinary related:
  • constipation
  • nausea or vomiting
  • difficulty urinating
Neurological and behavior related:
  • dizziness
  • drowsiness
  • headache
  • becoming extremely sensitive to touch
Allergy related:
  • sweating
Breathing related:
  • sleep apnoea (temporarily stop breathing while you sleep)
Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
Breathing related:
  • difficulty breathing or shallow breathing
Neurological and behavior related:
  • light-headedness, fainting or dizziness especially when standing up
  • changes in mood
  • drowsiness or feeling extremely sedated
  • feeling disorientated and having nightmares
Heart related:
  • slow or noticeable heartbeats
Gastrointestinal and urinary related:
  • severe stomach pain with nausea or vomiting
  • difficulty urinating
Allergy related:
  • shortness of breath, swelling of the face, lips, tongue or other parts of the body
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What MS MONO capsules contain

Active ingredient
(main ingredient)
Morphine sulfate pentahydrate
Other ingredients
(inactive ingredients)
Hydrogenated vegetable oil
Macrogol 6000
Magnesium stearate
Purified talc.
Capsule shell:
Gelatin
Sodium lauryl sulfate
Black ink print:
Shellac
Iron oxide black (E172 / CI77499)
Propylene glycol
Colorants:
Titanium dioxide (E171)
Erythrosine (E127 / CI45430) (90 mg)
Indigo carmine (E132 / CI73015) (30 mg, 60 mg and 120 mg)
Iron oxide black (E172 / CI77499) (90 mg and 120 mg)
Iron oxide red (E172 / CI77491) (60 mg and 90 mg)
Iron oxide yellow (E172 / CI77492) (60 mg and 120 mg)

Do not take this medicine if you are allergic to any of these ingredients.

What MS MONO capsules looks like

MS MONO modified release capsules are available in four strengths packed in blister packs of 14 capsules.

MS MONO capsules 30 mg - light blue, size 4 capsules marked MS OD 30 (Aust R 74156)

MS MONO capsules 60 mg - brown, size 3 capsules marked MS OD 60 (Aust R 74154)

MS MONO capsules 90 mg - pink, size 2 capsules marked MS OD 90 (Aust R 74152)

MS MONO capsules 120 mg - olive, size 1 capsules marked MSOD 120 (Aust R 74150)

Who distributes MS MONO capsules

Mundipharma Pty Limited
ABN 87 081 322 509
10 Carrington Street
SYDNEY NSW 2000
Phone: 1800 188 009

This leaflet was prepared in May 2023

® MS MONO is a trade mark of MUNDIPHARMA.
MS MONO-CMIv1-CCDSv19

Published by MIMS July 2023

BRAND INFORMATION

Brand name

MS Mono

Active ingredient

Morphine sulfate pentahydrate

Schedule

S8

 

Boxed Warnings

Limitations of use. Because of the risks associated with the use of opioids, MS Mono capsules should only be used in patients for whom other treatment options, including non-opioid analgesics, are ineffective, not tolerated or otherwise inadequate to provide appropriate management of pain (see Section 4.4 Special Warnings and Precautions for Use).
Hazardous and harmful use. MS Mono capsules pose risks of hazardous and harmful use which can lead to overdose and death. Assess the patient's risk of hazardous and harmful use before prescribing and monitor the patient regularly during treatment (see Section 4.4 Special Warnings and Precautions for Use).
Life threatening respiratory depression. Serious, life-threatening or fatal respiratory depression may occur with the use of MS Mono capsules. Be aware of situations which increase the risk of respiratory depression, modify dosing in patients at risk and monitor patients closely, especially on initiation or following a dose increase (see Section 4.4 Special Warnings and Precautions for Use).
Concomitant use of benzodiazepines and other central nervous system (CNS) depressants, including alcohol. Concomitant use of opioids with benzodiazepines, gabapentinoids, antihistamines, tricyclic antidepressants, antipsychotics, cannabis or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Limit dosages and durations to the minimum required; and monitor patients for signs and symptoms of respiratory depression and sedation. Caution patients not to drink alcohol while taking MS Mono capsules.

1 Name of Medicine

Morphine sulfate pentahydrate.

2 Qualitative and Quantitative Composition

MS Mono capsules are a range of modified release capsules containing a multi-particulate formulation of morphine sulfate pentahydrate.
MS Mono modified release capsules 30 mg contains 30 mg of morphine sulfate pentahydrate.
MS Mono modified release capsules 60 mg contains 60 mg of morphine sulfate pentahydrate.
MS Mono modified release capsules 90 mg contains 90 mg of morphine sulfate pentahydrate.
MS Mono modified release capsules 120 mg contains 120 mg of morphine sulfate pentahydrate.

3 Pharmaceutical Form

MS Mono modified release capsules 30 mg - size 4, light blue capsules, containing white to off white multi particulates 0.25 to 1.8 mm in diameter, marked MS OD 30 in black ink.
MS Mono modified release capsules 60 mg - size 3, brown capsules, containing white to off white multi particulates 0.25 to 1.8 mm in diameter, marked MS OD 60 in black ink.
MS Mono modified release capsules 90 mg - size 2, pink capsules, containing white to off white multi particulates 0.25 to 1.8 mm in diameter, marked MS OD 90 in black ink.
MS Mono modified release capsules 120 mg - size 1, olive capsules, containing white to off white multi particulates 0.25 to 1.8 mm in diameter, marked MS OD 120 in black ink.

4 Clinical Particulars

4.9 Overdose

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).
Symptoms. Serious morphine overdosage is characterised by respiratory depression (reduced respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, pneumonia aspiration, miotic pupils, rhabdomyolysis progressing to renal failure, flaccidity of skeletal muscle, cold or clammy skin, and sometimes hypotension and bradycardia. Severe overdosage may result in apnoea, pulmonary oedema, circulatory collapse, cardiac arrest and death.
Treatment. Primary attention should be given to the establishment of adequate respiratory exchange through the provision of a patent airway and controlled or assisted ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote against respiratory depression due to overdosage or as a result of unusual sensitivity to morphine. An appropriate dose of one of the antagonists should therefore be administered, preferably by the intravenous route. The usual initial intravenous (IV) adult dose of naloxone is 0.4 mg or higher (please refer to naloxone product information for further information). Concomitant efforts at respiratory resuscitation should be carried out. Since the duration of action of morphine, particularly sustained release formulations, may exceed that of the antagonist, the patient should be under continued surveillance and doses of the antagonist should be repeated as needed to maintain adequate respiration.
An antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression. Oxygen, intravenous fluids, vasopressors and other supportive measures should be used as indicated to manage the circulatory shock accompanying an overdose. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation. Artificial ventilation should be applied if necessary and fluid and electrolyte metabolism maintained.
In an individual physically dependent on opioids, the administration of the usual dose of opioid antagonist will precipitate an acute withdrawal syndrome. The severity of this syndrome will depend on the degree of physical dependence and the dose of antagonist administered. The use of opioid antagonists in such individuals should be avoided if possible. If an opioid antagonist must be used to treat serious respiratory depression in the physically dependent patient, the antagonist should be administered with extreme care by using dosage titration, commencing with 10 to 20% of the usual recommended initial dose.
Whole bowel irrigation (e.g. one or two litres of polyethylene glycol solution orally per hour until rectal effluent is clear) may be useful for gut decontamination.
Prolonged periods of observation (days) may be required for patients who have overdosed with long acting morphine preparations.
Toxicity. Morphine toxicity may result from overdosage but because of the great interindividual variation in sensitivity to opioids it is difficult to determine an exact dose of any opioid that is toxic or lethal. Chewing or crushing and taking the contents of a modified release dosage form leads to the release of the morphine in an immediate fashion; this might result in a fatal overdose.
The presence of pain or tolerance tends to diminish the toxic effects of morphine. Published data suggest that in a morphine naive, pain free individual, the lethal dose would be in excess of 120 mg. Patients on chronic oral morphine therapy have been known to take in excess of 3000 mg/day with no apparent toxicity.

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. No regulatory studies to assess the mutagenic potential of morphine have been conducted.
Carcinogenicity. Regulatory studies in animals to evaluate the carcinogenic potential of morphine have not been conducted.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Morphine sulfate pentahydrate is a white, odourless crystalline powder or needle-like crystals. Morphine sulfate pentahydrate has solubility of 1:21 in water and 1:1000 in ethanol. The chemical name is 7,8-didehydro-4,5α-epoxy -17-methylmorphinan-3,6α-diol sulfate salt (2:1) pentahydrate. It is practically insoluble in ether or chloroform.
Chemical structure. The structural formula of morphine sulfate pentahydrate is:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSMORSUP.gif CAS number. 6211-15-0.

7 Medicine Schedule (Poisons Standard)

S8.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/MSMONOST.gif